Literature DB >> 17727326

MicroRNA expression in lymphoma.

Charles H Lawrie1.   

Abstract

MicroRNAs are a recently discovered class of short (approximately 22 nucleotide) naturally occurring RNA molecules that negatively regulate gene expression post-transcriptionally. There has been an explosion of interest in the microRNA field as these molecules have been found to play key roles in a wide range of biological processes and to be aberrantly expressed in many types of cancer, including haematological malignancies. Cancer-associated microRNAs can act as both tumour suppressor molecules (e.g., miR-15a and miR-16-1) and have oncogenic properties (e.g., miR-155 and miR-17-92 cluster). In this review the authors discuss the rapidly accumulating evidence for the central role that microRNAs play in both haematopoiesis and haematological malignancy, in particular focusing on their role in lymphoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17727326     DOI: 10.1517/14712598.7.9.1363

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  21 in total

Review 1.  Non-coding RNAs in cancer initiation and progression and as novel biomarkers.

Authors:  S Patrick Nana-Sinkam; Carlo M Croce
Journal:  Mol Oncol       Date:  2011-10-31       Impact factor: 6.603

2.  Diagnostic, prognostic and predictive value of MicroRNA-21 in breast cancer patients, their daughters and healthy individuals.

Authors:  Ambreen Usmani; Amir Ali Shoro; Zahida Memon; Mehvish Hussain; Rehana Rehman
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

Review 3.  MicroRNAs in immune regulation--opportunities for cancer immunotherapy.

Authors:  Hideho Okada; Gary Kohanbash; Michael T Lotze
Journal:  Int J Biochem Cell Biol       Date:  2010-02-06       Impact factor: 5.085

4.  MYC chromosomal aberration in differential diagnosis between Burkitt and other aggressive lymphomas.

Authors:  Gabriella Aquino; Laura Marra; Monica Cantile; Annarosaria De Chiara; Giuseppina Liguori; Maria Pia Curcio; Rocco Sabatino; Giuseppe Pannone; Antonio Pinto; Gerardo Botti; Renato Franco
Journal:  Infect Agent Cancer       Date:  2013-09-30       Impact factor: 2.965

5.  miRNA expression profiling of mycosis fungoides.

Authors:  Marloes S van Kester; Erica Ballabio; Marchina F Benner; Xiao H Chen; Nigel J Saunders; Leslie van der Fits; Remco van Doorn; Maarten H Vermeer; Rein Willemze; Cornelis P Tensen; Charles H Lawrie
Journal:  Mol Oncol       Date:  2011-02-24       Impact factor: 6.603

6.  Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity.

Authors:  Akemi Kosaka; Takayuki Ohkuri; Maki Ikeura; Gary Kohanbash; Hideho Okada
Journal:  Biochem Biophys Res Commun       Date:  2015-02-10       Impact factor: 3.575

7.  miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy.

Authors:  Kotaro Sasaki; Gary Kohanbash; Aki Hoji; Ryo Ueda; Heather A McDonald; Todd A Reinhart; Jeremy Martinson; Michael T Lotze; Francesco M Marincola; Ena Wang; Mitsugu Fujita; Hideho Okada
Journal:  J Transl Med       Date:  2010-02-18       Impact factor: 5.531

8.  miRNAs expression analysis in paired fresh/frozen and dissected formalin fixed and paraffin embedded glioblastoma using real-time pCR.

Authors:  Dario de Biase; Michela Visani; Luca Morandi; Gianluca Marucci; Cristian Taccioli; Serenella Cerasoli; Agostino Baruzzi; Annalisa Pession
Journal:  PLoS One       Date:  2012-04-18       Impact factor: 3.240

9.  miR-18a impairs DNA damage response through downregulation of ataxia telangiectasia mutated (ATM) kinase.

Authors:  Libing Song; Chuyong Lin; Zhiqiang Wu; Hui Gong; Yong Zeng; Jueheng Wu; Mengfeng Li; Jun Li
Journal:  PLoS One       Date:  2011-09-27       Impact factor: 3.240

10.  A quantitative PCR method to detect blood microRNAs associated with tumorigenesis in transgenic mice.

Authors:  Alice C Fan; Marianna M Goldrick; Jennifer Ho; Yu Liang; Pavan Bachireddy; Dean W Felsher
Journal:  Mol Cancer       Date:  2008-09-30       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.